StageZero Life Sciences Ltd. (SZLSF)

USD 0.0

(0.0%)

Market Cap (In USD)

1.29 Million

Revenue (In USD)

3.79 Million

Net Income (In USD)

-11.41 Million

Avg. Volume

2454.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.0015-0.9999
PE
-
EPS
-
Beta Value
0.078
ISIN
CA8525403017
CUSIP
852540301
CIK
1454263
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. James R. Howard-Tripp
Employee Count
-
Website
https://www.stagezerolifesciences.com
Ipo Date
2009-09-08
Details
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.